23andme is the leading personal genetics company dedicated to helping individuals understand their own genetic information through dna analysis technologies and web-based interactive tools. the company's personal genome service® enables individuals to gain deeper insights into their ancestry and genetic make-up. the vision for 23andme is to personalize healthcare by making and supporting meaningful discoveries through genetic research. 23andme was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science.
Company profile
Ticker
ME
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Bleecker Street Acquisition Corp., VG Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
23andMe, Inc. • Lemonaid Health Inc. • Lemonaid Health Limited ...
ME stock data
Latest filings (excl ownership)
8-K
23andMe announces CEO’s intention to pursue a potential take-private
18 Apr 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
S-8
Registration of securities for employees
22 Mar 24
10-Q
2024 Q3
Quarterly report
7 Feb 24
8-K
23andMe Reports Third Quarter Fiscal 2024 Financial Results
7 Feb 24
8-K
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
31 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K/A
Regulation FD Disclosure
1 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Nov 23
8-K
23andMe Reports Second Quarter Fiscal 2024 Financial Results
8 Nov 23
Transcripts
ME
Earnings call transcript
2024 Q2
8 Nov 23
ME
Earnings call transcript
2024 Q1
8 Aug 23
ME
Earnings call transcript
2023 Q4
25 May 23
ME
Earnings call transcript
2023 Q3
8 Feb 23
ME
Earnings call transcript
2023 Q2
8 Nov 22
ME
Earnings call transcript
2023 Q1
9 Aug 22
ME
Earnings call transcript
2022 Q4
27 May 22
ME
Earnings call transcript
2022 Q3
11 Feb 22
ME
Earnings call transcript
2021 Q2
11 Nov 21
ME
Earnings call transcript
2022 Q1
13 Aug 21
Latest ownership filings
4
KATHY L HIBBS
19 Apr 24
SC 13D/A
ABeeC 2.0, LLC
17 Apr 24
4
KATHY L HIBBS
5 Apr 24
4
KATHY L HIBBS
22 Mar 24
4
KATHY L HIBBS
11 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
4
KATHY L HIBBS
23 Feb 24
4
William G Richards
21 Feb 24
4
Joseph Anthony Selsavage
21 Feb 24
4
KATHY L HIBBS
21 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 264.76 mm | 264.76 mm | 264.76 mm | 264.76 mm | 264.76 mm | 264.76 mm |
Cash burn (monthly) | 19.32 mm | 12.89 mm | 26.38 mm | 29.56 mm | 19.04 mm | 12.16 mm |
Cash used (since last report) | 129.22 mm | 86.22 mm | 176.41 mm | 197.73 mm | 127.34 mm | 81.31 mm |
Cash remaining | 135.53 mm | 178.54 mm | 88.35 mm | 67.03 mm | 137.42 mm | 183.45 mm |
Runway (months of cash) | 7.0 | 13.8 | 3.3 | 2.3 | 7.2 | 15.1 |
Institutional ownership, Q3 2023
92.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 169 |
Opened positions | 15 |
Closed positions | 19 |
Increased positions | 60 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 131.88 bn |
Total shares | 291.31 mm |
Total puts | 223.30 k |
Total calls | 502.60 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
ABeeC 2.0 | 98.63 mm | $1.08 bn |
GSK GSK | 39.66 mm | $116.21 mm |
Vanguard | 28.15 mm | $27.52 bn |
BLK Blackrock | 19.60 mm | $19.16 bn |
NewView Capital Partners I | 19.46 mm | $19.07 bn |
NewView Capital Fund I | 19.46 mm | $0.00 |
Euclidean Capital | 10.24 mm | $10.01 bn |
FMR | 6.70 mm | $6.55 bn |
STT State Street | 6.61 mm | $6.47 bn |
Geode Capital Management | 6.12 mm | $5.99 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Kathy L Hibbs | Class A Common Stock | Sell | Dispose S | No | Yes | 0.4708 | 38,548 | 18.15 k | 1,252,315 |
18 Apr 24 | Kathy L Hibbs | Class A Common Stock | Option exercise | Acquire M | No | No | 0.42 | 38,548 | 16.19 k | 1,290,863 |
18 Apr 24 | Kathy L Hibbs | Stock Option Class A Common Stock | Option exercise | Dispose M | No | No | 0.42 | 38,548 | 16.19 k | 38,551 |
4 Apr 24 | Kathy L Hibbs | Class A Common Stock | Sell | Dispose S | No | Yes | 0.5002 | 38,548 | 19.28 k | 1,252,315 |
4 Apr 24 | Kathy L Hibbs | Class A Common Stock | Option exercise | Acquire M | No | No | 0.42 | 38,548 | 16.19 k | 1,290,863 |
4 Apr 24 | Kathy L Hibbs | Stock Option Class A Common Stock | Option exercise | Dispose M | No | No | 0.42 | 38,548 | 16.19 k | 77,099 |
21 Mar 24 | Kathy L Hibbs | Class A Common Stock | Sell | Dispose S | No | Yes | 0.4642 | 38,548 | 17.89 k | 1,252,315 |
21 Mar 24 | Kathy L Hibbs | Class A Common Stock | Option exercise | Acquire M | No | No | 0.42 | 38,548 | 16.19 k | 1,290,863 |
21 Mar 24 | Kathy L Hibbs | Stock Option Class A Common Stock | Option exercise | Dispose M | No | No | 0.42 | 38,548 | 16.19 k | 115,647 |
7 Mar 24 | Kathy L Hibbs | Class A Common Stock | Sell | Dispose S | No | Yes | 0.53 | 38,548 | 20.43 k | 1,252,315 |